Immunome (IMNM) Q3 FY2026 earnings: revenue $0

Immunome Inc. (IMNM) reported revenue of $0 for Q3 FY2026, the quarter ended 30 September 2026. Net income was -$86 million, and diluted earnings per share $-0.76. The figures are the company's own, from the 10-Q it filed with the SEC on 9 November 2026.

Revenue

Q4 FY2024Q3 FY2026

Operating margin

n/a

Q4 FY2024Q3 FY2026

Net income

-$86 million

Q4 FY2024Q3 FY2026

Diluted EPS

-$0.76

Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 1 new, 5 kept.

Net loss widened to $85.8M: The company reported a net loss of $85.8 million, or $(0.76) per diluted share, against $57.5 million, or $(0.65) per share, a year earlier. Collaboration revenue was nil in both quarters.
FDA action date set for April 2027: The FDA accepted the varegacestat NDA in July 2026 and set a PDUFA target action date of April 28, 2027, for adults with desmoid tumors.
EMA validated the MAA: The European Medicines Agency validated the MAA for varegacestat in October 2026, for the same adult desmoid tumor indication.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Revenue	0.0	0.0	0.0
Research and development	69.5	59.9	49.2	+16.1%	+41.3%
Operating income	-90.4	-78.1	-60.1
Net income	-85.8	-73.1	-57.5
Diluted EPS	-$0.76	-$0.65	-$0.65

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Operating cash flow	-60.8	-61.7	-40.5
Capital expenditure	0.5	2.2	1.1	-77.5%	-56.2%
Free cash flow	-61.2	-63.9	-41.6
Cash from investing	53.5	-304	124		-56.8%
Cash from financing	2.4	1.1	45.4	+124.6%	-94.8%
Depreciation and amortisation	1.0	1.0	0.6	+4.9%	+70.5%
Share-based compensation	12.8	8.8	6.7	+45.0%	+89.1%
Diluted shares, weighted	114m	113m	88m	+0.3%	+29.1%
Shares outstanding at period end	114m	113m	92m	+0.2%	+23.9%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Shareholders' equity	454	525	264	-13.5%	+72.1%
Debt	0.0	0.0	0.0
Operating lease liabilities	10.3	4.6	4.0	+123.6%	+155.6%
Other liabilities	41.0	35.7	31.4	+14.7%	+30.3%
Total liabilities and equity	506	565	299	-10.6%	+68.9%
Fixed assets	16.7	17.4	11.6	-4.0%	+44.2%
Investments	249	302	0.0	-17.7%
Cash and equivalents	213	218	273	-2.2%	-21.9%
Other assets	27.3	28.0	15.2	-2.7%	+79.7%
Total assets	506	565	299	-10.6%	+68.9%

Questions

What was Immunome's revenue in Q3 FY2026?

Immunome (IMNM) reported revenue of $0 for Q3 FY2026, the quarter ended 30 September 2026.

How much did Immunome earn in Q3 FY2026?

Net loss for Q3 FY2026 was $86 million, and the diluted loss per share $0.76.

When did Immunome report Q3 FY2026 results?

Immunome filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 9 November 2026.

Quarterly results, the last 15 quarters

	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	2.4	4.3	3.6	3.8	1.0	2.4	2.9	2.7	2.9	4.0	0.0	0.0	0.0	0.0	0.0
R&D	3.9	5.7	3.8	9.6	15.4	29.1	37.2	47.9	36.9	40.5	49.2	50.8	46.4	59.9	69.5
Operating income	-4.5	-5.8	-4.6	-94.7	-132	-40.0	-50.5	-83.0	-44.6	-46.5	-60.1	-72.9	-59.3	-78.1	-90.4
Operating margin	-189%	-135%	-130%	-2474%	-12857%	-1692%	-1736%	-3030%	-1525%	-1158%	n/a	n/a	n/a	n/a	n/a
Net income	-4.3	-5.6	-4.3	-92.6	-129	-36.1	-47.1	-80.2	-41.6	-43.4	-57.5	-69.9	-53.8	-73.1	-85.8
Net margin	-181%	-130%	-122%	-2421%	-12584%	-1528%	-1619%	-2931%	-1423%	-1081%	n/a	n/a	n/a	n/a	n/a
Diluted EPS	-$0.35	-$0.46	-$0.36	-$4.21	-$2.51	-$0.60	-$0.78	n/a	-$0.52	-$0.50	-$0.65	-$0.76	-$0.48	-$0.65	-$0.76
Operating cash flow	24.2	-5.7	-8.6	-17.5	-11.2	-23.4	-34.2	-42.1	-53.1	-49.4	-40.5	-48.0	-58.6	-61.7	-60.8
Capital expenditure	0.1	0.3	0.0	0.3	2.2	2.3	1.5	1.1	3.7	0.9	1.1	4.0	3.0	2.2	0.5
Free cash flow	24.1	-6.0	-8.7	-17.8	-13.3	-25.7	-35.7	-43.2	-56.7	-50.3	-41.6	-52.0	-61.6	-63.9	-61.2
Shares outstanding	12m	12m	12m	43m	60m	60m	60m	64m	87m	87m	92m	113m	113m	113m	114m
Filing	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A blank figure marked on a quarter is one the filings do not give on their own: the quarters as filed do not add to the year the company filed, or the year and its quarters stand on different share counts. Each quarter's page says which. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 9 November 2026: the filing.